Key result
The C allele of the AT1R A1166C polymorphism was associated with a lower endothelial response to statin treatment compared to the AA genotype.
Why the study?
Does the A1166C polymorphism of the AT1R gene alter endothelial response to statin treatment in patients with coronary artery disease or hypercholesterolemia?
Cohort (n=44)
Does the A1166C polymorphism of the AT1R gene alter endothelial response to statin treatment in patients with coronary artery disease or hypercholesterolemia?
The C allele of the AT1R A1166C polymorphism is associated with a significantly lower endothelial response to statin treatment.
Answers are grounded in this paper and cite their sources.
AT1R A1166C genotyping should not guide statin therapy in CAD; leaves open pharmacogenomic effects on endothelial response.
BACKGROUND: The function of vascular endothelium is influenced by several factors: low-density lipoprotein (LDL) cholesterol, oxidative stress and the reninangiotensin system. METHODS: We tested the hypothesis that polymorphisms A1166C of the angiotensin AT1 receptor (AT1R) gene, C242T and A640G of the pphox22 gene (p22 phox is an essential component of NADH/NADPH oxidases) and G894T of the endothelial nitric oxide (NO) synthase (eNOS) gene influence endothelial function and its reaction to statin treatment. In 44 patients with coronary artery disease or hypercholesterolemia (not on lipid-lowering treatment), lipid profile and endothelial function (brachial artery flow-mediated dilation, FMD) were measured at baseline and after treatment with statins for 8-12 weeks. All subjects were genotyped for the above-mentioned polymorphisms. RESULTS: None of the polymorphisms significantly predicted baseline FMD. Patients with the C allele of A1166C showed smaller changes in FMD in comparison with patients with the AA genotype (-0.044+/-0.439% vs. 0.386+/-0.599%; p=0.016). None of the other polymorphisms significantly influenced changes in FMD. CONCLUSIONS: The C allele of AT1R A1166C is associated with significantly lower endothelial response to statin treatment.
No takes yet. Share an insight, caveat, or question.
Kiliszek et al. (2007) conducted a cohort in Coronary artery disease or hypercholesterolemia (n=44). C allele of AT1R A1166C polymorphism vs. AA genotype was evaluated on Changes in flow-mediated dilation (FMD) (p=0.016). The C allele of the AT1R A1166C polymorphism was associated with a lower endothelial response to statin treatment compared to the AA genotype.
Synapse has enriched 10 related papers. Consider them for comparative context: